retatrutide how long to see results does last: complete shelf life, storage, and duration guide retatrutide trial data New Phase

Renal protection with glucagon-like peptide type 1 receptor agonists In CVOTs of arGLP1 renal outcomes were prespecified as key secondary outcomes in 4 studies done with liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatide,58,59,63,64 or were collected as safety parameters in other studies.60 Overall, the prevalence of CKD stage 3 in these studies was low (2030%) (Table 1)

Under the guidance of a qualified healthcare provider, these medications are prescribed at doses significantly lower than those typically used for diabetes or major weight loss

Kushnir M, Gali R, Alexander M, Billett HHH

I have lost 9lbs so far

Evidence for Cardiovascular Safety The DPP-4 inhibitors have not demonstrated any sustained or clinically significant reduction in other cardiovascular risk factors, such as blood pressure or lipids